XNASICCC
Market cap46mUSD
Jan 08, Last price
5.17USD
1D
-4.44%
1Q
39.73%
Jan 2017
-13.11%
Name
ImmuCell Corp
Chart & Performance
Profile
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 17,472 -5.90% | 18,568 -3.51% | |||||||
Cost of revenue | 22,693 | 23,131 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (5,221) | (4,563) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 5 | 8 | |||||||
Tax Rate | |||||||||
NOPAT | (5,226) | (4,571) | |||||||
Net income | (5,775) 131.54% | (2,494) 3,097.44% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 30,670 | ||||||||
BB yield | -64.92% | ||||||||
Debt | |||||||||
Debt current | 2,073 | 1,071 | |||||||
Long-term debt | 19,339 | 13,658 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 20,433 | 8,937 | |||||||
Cash flow | |||||||||
Cash from operating activities | (4,674) | (1,544) | |||||||
CAPEX | (1,893) | (3,975) | |||||||
Cash from investing activities | (1,890) | (3,964) | |||||||
Cash from financing activities | 1,751 | 1,114 | |||||||
FCF | (8,862) | (8,983) | |||||||
Balance | |||||||||
Cash | 979 | 5,792 | |||||||
Long term investments | |||||||||
Excess cash | 105 | 4,864 | |||||||
Stockholders' equity | (11,226) | (5,451) | |||||||
Invested Capital | 52,909 | 48,306 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 7,748 | 7,745 | |||||||
Price | 5.09 -16.56% | 6.10 -23.75% | |||||||
Market cap | 39,436 -16.53% | 47,245 -22.22% | |||||||
EV | 59,869 | 56,182 | |||||||
EBITDA | (5,221) | (2,075) | |||||||
EV/EBITDA | |||||||||
Interest | 341 | ||||||||
Interest/NOPBT |